Back to top
more

Ligand Pharmaceuticals (LGND)

(Delayed Data from NSDQ)

$80.06 USD

80.06
85,117

-1.28 (-1.57%)

Updated Jun 14, 2024 04:00 PM ET

After-Market: $80.25 +0.19 (0.24%) 7:58 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy24.08%
2Buy17.91%
3Hold9.44%
4Sell5.10%
5Strong Sell2.55%
S&P50011.04%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

2-Buy of 5   2      

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

C Value F Growth B Momentum D VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 36% (89 out of 250)

Industry: Medical - Biomedical and Genetics

Better trading starts here.

Zacks News

Why You Should Add Encompass Health (EHC) to Your Portfolio Now

Encompass Health (EHC) remains well-poised for growth on the back of robust demand for effective inpatient rehabilitation services, joint ventures and solid cash reserves.

Vanda (VNDA) Rises on Positive Data From Motion Sickness Study

Vanda's (VNDA) tradipitant appears effective in preventing vomiting associated with motion sickness in a second phase III study. Stock rises on the news.

Bristol Myers (BMY) Gets FDA Nod for Breyanzi Label Expansion

Bristol Myers Squibb (BMY) obtains FDA approval for the label expansion of CAR T cell therapy Breyanzi to treat adult patients with relapsed or refractory follicular lymphoma.

FDA Delays Decision on Ascendis' (ASND) Hormone Therapy Filing

Per the FDA, the data submitted by Ascendis (ASND) for its hormone replacement therapy constitutes a major amendment to its previously-submitted data. A final decision is expected by Aug 14.

Allogene (ALLO) Q1 Earnings in Line With Estimates, Sales Lag

Allogene (ALLO) reports drab first-quarter 2024 results. The company secures the development and marketing rights to its CD19 oncology program in Europe.

Novo Nordisk (NVO) Up 3% as Haemophilia Drug Meets Study Goals

Novo Nordisk's (NVO) shares rise 3.1% as the company meets co-primary endpoints in a late-stage study evaluating its investigational candidate, Mim8, for the treatment of haemophilia A.

Merck (MRK) Ends Keytruda Combo Melanoma Study Due to Futility

Merck (MRK) discontinues the Keytruda plus vibostolimab co-formulation arm of a phase III study due to a higher rate of patient discontinuation.

Bayer (BAYRY) Q1 Earnings Fall Y/Y on Lower Product Sales

Bayer's (BAYRY) Q1 earnings and sales decline year over year due to a fall in volumes for non-glyphosate-based herbicides and lower prices for glyphosate-based products in the Crop Science division.

Ligand (LGND) Moves to Strong Buy: Rationale Behind the Upgrade

Ligand (LGND) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #1 (Strong Buy).

Moderna (MRNA) Falls as FDA Extends Review Time for RSV Vaccine

Moderna's (MRNA) RSV vaccine, mRNA-1345's review timeline gets delayed. A decision is now expected by the end of May.

Bristol Myers (BMY) Fails to Meet Goal in Opdivo NSCLC Study

Bristol Myers' (BMY) late-stage label-expanding study evaluating the Opdivo/Yervoy combination fails to meet the primary endpoint of progression-free survival in unresectable stage III NSCLC.

Sanofi (SNY), Regeneron's Dupixent sBLA Gets FDA Priority Tag

Sanofi (SNY) and Regeneron's (REGN) Dupixent is poised to be the first medicine for adolescents with inadequately controlled CRSwNP, if approved by the FDA.

Nektar's (NKTR) Q1 Earnings and Revenues Surpass Estimates

Nektar (NKTR) reports a narrower-than-expected loss in the first quarter of 2024 and tops revenue estimates.

Insmed (INSM) Beats on Q1 Earnings, Posts Upbeat Pipeline Updates

Insmed (INSM) Q1 earnings beat estimates while sales miss the mark. Management posts positive data readouts from mid-stage studies on its experimental inhalation powder in PH-ILD and PAH indications.

Iovance (IOVA) Q1 Earnings Surpass, Sales Lag Estimates

Iovance (IOVA) reports mixed first-quarter results. Shares gain on encouraging initial demand for the recently-approved melanoma drug Amtagvi in the United States.

Amicus (FOLD) Q1 Earnings Top, Sales Lag, '24 Outlook Updated

Amicus (FOLD) reports first-quarter 2024 results, wherein earnings beat the Zacks Consensus Estimate but sales miss the same. The company updates its financial guidance for 2024.

Ligand (LGND) Is a Great Choice for 'Trend' Investors, Here's Why

Ligand (LGND) made it through our "Recent Price Strength" screen and could be a great choice for investors looking to make a profit from stocks that are currently on the move.

Editas (EDIT) Q1 Earnings & Revenues Lag Estimates, Stock Down

Editas (EDIT) reports weaker-than-expected first-quarter 2024 results as both earnings and revenues fall shy of estimates. Shares fall.

TEVA Q1 Earnings Miss, Schizophrenia Study Meets Goal, Stock Up

TEVA reports mixed first-quarter results, missing estimates for earnings but beating the same for sales. It announces promising data from a phase III study on schizophrenia candidate, olanzapine.

Mirum's (MIRM) Q1 Earnings & Revenues Fall Shy of Estimates

Mirum's (MIRM) earnings and revenues miss estimates in the first quarter of 2024. Livmarli drives year-over-year sales.

Catalyst (CPRX) Q1 Earnings Beat, Firdapse Sales Drive Revenues

Catalyst (CPRX) reports first-quarter results, wherein earnings and revenues beat the Zacks Consensus Estimate, driven by strong Firdapse sales.

Viatris' (VTRS) Q1 Earnings & Sales Lag Estimates, Stock Down

Viatris (VTRS) Q1 numbers fall short of estimates. The company adjusts the annual guidance to reflect the impact of divestitures.

CRISPR's (CRSP) Q1 Loss Narrower-Than-Expected, Sales Miss

CRISPR Therapeutics (CRSP) reports mixed earnings results for first-quarter 2024. Management claims that the commercial launch for the first ever CRISPR-based gene therapy is progressing well.

Are Medical Stocks Lagging Ligand Pharmaceuticals (LGND) This Year?

Here is how Ligand Pharmaceuticals (LGND) and Adverum Biotechnologies (ADVM) have performed compared to their sector so far this year.

Acadia (ACAD) Q1 Earnings Surpass Estimates, Revenues Miss

Acadia's (ACAD) earnings in the first quarter of 2024 beat the Zacks Consensus Estimate, while revenues miss the same.